First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    DexCom, Inc.

    DXCM · 4 developments mapped · last assessed 2026-09-23

    Market Ontology has mapped 4 macro, policy, and market developments to DexCom, Inc. since 2026-09-01. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for DXCM yet, so no modelled value is shown. The DXCM valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run DXCM on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for DXCM. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide

      Increased adoption of GLP-1/GIP drugs for type 2 diabetes and obesity may lead to a larger population requiring continuous glucose monitoring (CGM) for better disease management and monitoring of treatment efficacy.

      · Moves total addressable market for cgm devices, growth rate of cgm adoption

    • Open question

      MiniMed Group, Inc. Raises Fiscal Year 2027 Organic Revenue Growth Guidance

      Competitive dynamics and market share in the continuous glucose monitoring (CGM) market. Strong performance by a competitor could indicate a growing market but also increased competition.

      · Moves market share assumptions, revenue growth rate, competitive landscape

    What changed, by assumption

    Market share assumptions
    • 2026-09-01MiniMed Group, Inc. Raises Fiscal Year 2027 Organic Revenue Growth Guidance
    Total addressable market for cgm devices
    • 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide
    Market share projections in diabetes care
    • 2026-09-14MiniMed Group, Inc. and Medtronic plc File Communication Regarding Business Combination
    Competitive intensity
    • 2026-09-14Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for EnicepatideBullish1-5y0.30
    2026-09-14MiniMed Group, Inc. and Medtronic plc File Communication Regarding Business Combinationwatch3-12m0.30
    2026-09-14Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.watch3-12m0.30
    2026-09-01MiniMed Group, Inc. Raises Fiscal Year 2027 Organic Revenue Growth Guidancemixed1-3m0.40